Promising data show complete responses observed across multiple subtypes of Epstein-Barr virus positive (EBV+) lymphoma; preliminary ORR/CR of 80%/40% in T/NK-NHL and 66%/33% in DLBCL
Recent End of Phase 2 Meeting supports advancement into single-arm registration trial
Registration trial for the treatment of relapsed/refractory EBV+ lymphomas to begin in 1H2021
PR Newswire
SAN DIEGO, Dec. 7, 2020